Today: 26 January 2026
Subscribe
Browse Category

Investment Tips News 24 September 2025 - 11 October 2025

Rolex Price “Crash”? Experts Say It’s Just a Healthy Correction

Rolex Price “Crash”? Experts Say It’s Just a Healthy Correction

Post-Boom Reality Check: Why Prices Are Falling During the COVID lockdown and recovery (2020–22), Rolex prices on the secondary market soared to unprecedented highs. Super-rare models were trading at multiples of retail (for example, the Tiffany Blue Oyster Perpetual jumped from ~$5K retail to £30K used Inkl). This “mania” phase saw average Rolex values nearly double in just two years Quillandpad. However, that…
11 October 2025
·
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease Newamsterdampharma. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion…
11 October 2025
··
TSMC Stock Tops $300 as AI Chip Boom Fuels Rally – Can It Keep Climbing? (Oct 2025 Update)

TSMC Stock Tops $300 as AI Chip Boom Fuels Rally – Can It Keep Climbing? (Oct 2025 Update)

Overview: TSMC’s Business and Recent Performance Taiwan Semiconductor Manufacturing Co. (TSMC) is the world’s largest contract chipmaker – a “pure-play” foundry that fabricates advanced semiconductors for clients like Apple, NVIDIA, AMD and more ts2.tech. Rather than selling its own chips, TSMC builds chips to order, focusing on cutting-edge manufacturing processes. This model has made TSMC a pillar of global tech…
9 October 2025
····
AI‑Powered Future: ABB Stock Soars After Mega Robotics Deal – What Investors Need to Know Now

AI‑Powered Future: ABB Stock Soars After Mega Robotics Deal – What Investors Need to Know Now

Key Facts (as of 8 Oct 2025) Metric Value Evidence Stock price ~58.46 CHF per share (closing price 7 Oct 2025 Digrin) with a forecast fair opening on 8 Oct of ~58.68 CHF Stockinvest. The stock had risen in seven of the prior ten trading days, gaining ~2.38 % over two weeks Stockinvest. Digrin, StockInvest Market cap ≈US$135 billion Companiesmarketcap. CompaniesMarketCap Trailing P/E ratio ~32.4× Companiesmarketcap (up from 25×…
8 October 2025
····
Orla Mining’s Gold Rush in 2025: Surging Prices, New Discoveries and What Investors Need to Know

Orla Mining’s Gold Rush in 2025: Surging Prices, New Discoveries and What Investors Need to Know

Metric Data/Comment Sources Latest trading price (6 Oct 2025) Orla Mining’s stock (NYSE: ORLA) closed at $16.40 per share on 6 Oct 2025. Investing.com’s historical table shows that on 6 Oct 2025 the shares opened at $14.59, hit a high of $16.40, a low of $14.57 and closed at $16.40, representing a 14.61 % gain on the day Investing. Investing.com Investing Pre‑market price (19 Sep 2025) On 19 Sept 2025, Yahoo…
6 October 2025
··
Advance Agrolife IPO Frenzy: 50x Subscription on Final Day, ₹115 Grey Market Listing & 15% Gains Expected

Advance Agrolife IPO Frenzy: 50x Subscription on Final Day, ₹115 Grey Market Listing & 15% Gains Expected

Advance Agrolife’s maiden public issue has garnered a feeding frenzy of investor interest. The ₹192.86 Cr IPO (19.3 million shares at ₹95–100) opened Sep 30 and closed Oct 3, 2025 Indiatimes Goodreturns. Data from NSE/IPO platforms show subscription surging on the final day: by 3:48 PM on Oct 3, total bids were 54.61 timesthe available shares Livemint. Retail bids were 20.57×, non-institutional (HNI) a staggering…
3 October 2025
····
Saudi Aramco Stock Analysis 2025: Is the Oil Giant Still Worth Your Money?

Saudi Aramco Stock Analysis 2025: Is the Oil Giant Still Worth Your Money?

2025 YTD Stock Performance Saudi Aramco’s stock (Tadawul: 2222.SR) started 2025 in the SR 22 range and rose above SR 24 by late September, giving a year‑to‑date gain of roughly 12 % Argaam. FinanceCharts data show the share price closing at SR 24.62 on 30 September, down 1.48 % from the previous day but up 3.45 % over the past 30 days Financecharts. Over the last twelve months the…
1 October 2025
····
All Aboard! Carnival Corp’s Stock Soars on Record Earnings and Booming Bookings

All Aboard! Carnival Corp’s Stock Soars on Record Earnings and Booming Bookings

Stock Performance Carnival’s stock has been on a steep climb in 2025. It traded near $15 as recently as late 2024, but by mid‑2025 it doubled to the low‑$30s. In September it has been consolidating at these highs: on Sep.26 it closed $30.62, then on Sep.29 it was around $31 Reuters. The shares finished the month near the top of…
29 September 2025
····
Tawana Resources (TAWNF) 2025 Stock Skyrocket: Lithium Revival or Mirage?

Tawana Resources (TAWNF) 2025 Stock Skyrocket: Lithium Revival or Mirage?

2025 Year-to-Date Stock Performance TAWNF’s stock chart for 2025 shows an eye-popping rise, gaining nearly 37-fold in value over the course of the year Marketbeat. On paper, this performance could entice any investor – but it comes with a huge caveat. The ticker symbol “TAWNF” was reassigned to Thai Airways International on OTC markets Marketbeat. In other words, the 2025 rally in TAWNF reflects…
24 September 2025
····
1 … 47 48 49

Stock Market Today

  • Hims & Hers Health (HIMS) Shares Drop Amid Valuation Debate After Volatile Trading
    January 26, 2026, 5:56 AM EST. Hims & Hers Health (NYSE:HIMS) shares fell 14% over the past month, extending a 37% slide over three months, despite a nearly 3x total return over three years. The stock closed at $29.62, trading well below a bullish fair value estimate of $173.02, based on expectations for strong revenue growth, rising profit margins, and high future earnings multiples typical of growth leaders. However, the current price-to-earnings (P/E) ratio of 50.4 times eclipses the healthcare sector average (23.4x) and peers (33.6x), raising concerns over valuation risk if growth forecasts falter. Key risks include telehealth demand shifts and regulatory changes affecting weight loss products. Investors face a trade-off: pay a premium for growth potential or reassess assumptions amid recent volatility and mixed momentum signals.
Go toTop